Weekly subcutaneous alemtuzumab and rituximab for relapsed CLL [chronic lymphocytic leukaemia].
Phase of Trial: Phase I
Latest Information Update: 16 May 2016
At a glance
- Drugs Alemtuzumab (Primary) ; Rituximab
- Indications Chronic lymphocytic leukaemia
- Focus Adverse reactions; Therapeutic Use
- 11 May 2016 Status changed from active, no longer recruiting to completed.
- 30 Nov 2012 Planned End Date changed from 1 Jul 2011 to 1 Dec 2014 as reported by ClinicalTrials.gov.
- 24 Mar 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.